Document is current

Any future updates will be listed below

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

Crossref DOI link: https://doi.org/10.1136/jitc-2020-001622

Published Online: 2020-12-21

Published Print: 2020-12

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark